Ruxolitinib (Jakafi) is a Janus kinase 1 and 2 small molecule inhibitor that the Food and Drug Administration approved for myelofibrosis and polycythemia vera. It has been expanded to off-label treatment for a variety of dermatologic conditions, with several clinical trials ongoing. A review of available studies and cases of off-label uses was performed to guide clinicians seeking evidence on the efficacy of this Janus kinase inhibitor for dermatologic disorders.
Materials and Methods
PubMed/MEDLINE, EMBASE, Scopus, and ClinicalTrials.gov databases were searched with the term “ruxolitinib,” and results were manually reviewed to identify published data on off-label uses of ruxolitinib. Studies included are structured by quality of evidence available.
Results
Ruxolitinib may have utility in the treatment of atopic dermatitis, psoriasis, and vitiligo, with data from open-label and randomized trials supporting efficacy of topical formulations. Evidence of utility for alopecia areata is mixed and differs depending on topical versus oral form. Evidence for numerous other conditions is available through case reports and case series.
Conclusions
There is growing evidence supporting potential off-label use of oral and topical ruxolitinib for a wide range of skin conditions. There are several ongoing investigations of ruxolitinib use in dermatology that will undoubtedly better define its efficacy and appropriate use in dermatology.
Get full access to this article
View all access options for this article.
References
1.
Jakafi (Ruxolitinib) [package insert]. Wilmington, DE: Incyte Corporation; 2020.
2.
HarrisonC, VannucchiAM. Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. Ther Adv Hematol, 2012; 3(6):341–354.
3.
VainchenkerW, LeroyE, GillesL, et al.JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Res, 2018; 7:82.
4.
KahnJ, DeverapalliSC, RosmarinD. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases. Semin Cutan Med Surg, 2018; 37(3):198–208.
5.
TegtmeyerK, ZhaoJ, MaloneyNJ, et al.Off-label studies on tofacitinib in dermatology: a review. J Dermatolog Treat, 2019; 1–11.
6.
LussanaF, CattaneoM, RambaldiA, et al.Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol, 2018; 93(3):339–347.
7.
Aboul-FettouhN, NijhawanRI. Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib. JAAD Case Rep, 2018; 4(5):455–457.
8.
Abikhair BurgoM, RoudianiN, ChenJ, et al.Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma. JCI Insight, 2018; 3(17):e120750.
9.
KhannaU, RichardsonV, HexnerE, et al.A photo-distributed papulopustular eruption and multiple squamous cell carcinomas in a patient on ruxolitinib. JAAD Case Rep, 2019; 5(10):895–897.
10.
RastrelliM, FerrazziB, TropeaS, et al.Aggressive Merkel cell carcinoma after Janus kinase inhibitor ruxolitinib for polycythemia vera. In Vivo, 2019; 33(5):1667–1669.
11.
RaedlerLA. Jakafi (ruxolitinib): first FDA-approved medication for the treatment of patients with polycythemia vera. Am Health Drug Benefits, 2015; 8:75–79.
12.
HoskingAM, JuhaszM, MesinkovskaNA. Topical Janus kinase inhibitors: a review of applications in dermatology. J Am Acad Dermatol, 2018; 79(3):535–544.
13.
EndNote X8.2. 2014. Philadelphia, PA United States: Clarivate Analytics.
14.
BramerWM, GiustiniD, de JongeGB, et al.De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc, 2016; 104(3):240–243.
15.
OuzzaniM, HammadyH, FedorowiczZ, et al.Rayyan—a web and mobile app for systematic reviews. Syst Rev, 2016; 5(1):210.
16.
OlsenEA, KornackiD, SunK, et al.Ruxolitinib cream for the treatment of patients with alopecia areata: a 2-part, double-blind, randomized, vehicle-controlled phase 2 study. J Am Acad Dermatol, 2020; 82(2):412–419.
17.
BokhariL, SinclairR. Treatment of alopecia universalis with topical Janus kinase inhibitors—a double blind, placebo, and active controlled pilot study. Int J Dermatol, 2018; 57(12):1464–1470.
18.
AlmutairiN, NourTM, HussainNH. Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study. Dermatology, 2019; 235(2):130–136.
19.
Mackay-WigganJ, JabbariA, NguyenN, et al.Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight, 2016; 1(15):e89790.
20.
KimBS, HowellMD, SunK, et al.Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol, 2020; 145(2):572–582.
21.
PunwaniN, BurnT, ScherleP, et al.Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor. Br J Dermatol, 2015; 173(4):989–997.
22.
PunwaniN, ScherleP, FloresR, et al.Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol, 2012; 67(4):658–664.
23.
RothsteinB, JoshipuraD, SaraiyaA, et al.Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol, 2017; 76(6):1054–1060.e1.
24.
LiuLY, KingBA. Ruxolitinib for the treatment of severe alopecia areata. J Am Acad Dermatol, 2019; 80:566–568.
25.
BayartCB, DeNiroKL, BrichtaL, et al.Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol, 2017; 77:167–170.
26.
XingL, DaiZ, JabbariA, et al.Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med, 2014; 20:1043–1049.
27.
VandiverA, GirardiN, AlhaririJ, et al.Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring. Int J Dermatol, 2017; 56:833–835.
28.
GordonSC, AbuduM, ZancanaroP, et al.Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata. J Eur Acad Dermatol Venereol, 2019; 33:e156–e157.
29.
BorgMA, ShalabiRA, ChildsR, et al.Alopecia universalis and chronic graft-vs-host disease treated with ruxolitinib. JAMA Dermatol, 2018; 154:1357–1358.
30.
DeebM, BeachRA. A case of topical ruxolitinib treatment failure in alopecia areata. J Cutan Med Surg, 2017; 21:562–563.
31.
HarrisJE, RashighiM, NguyenN, et al.Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol, 2016; 74:370–371.
32.
PetersonDM, VeselyMD. Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient. JAAD Case Rep, 2020; 6:257–259.
33.
CraiglowBG, TavaresD, KingBA. Topical ruxolitinib for the treatment of alopecia universalis. JAMA Dermatol, 2016; 152:490–491.
34.
PieriL, GuglielmelliP, VannucchiAM. Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am J Hematol, 2015; 90:82–83.
35.
RamotY, ZlotogorskiA. Complete regrowth of beard hair with ruxolitinib in an alopecia universalis patient. Skin Appendage Disord, 2018; 4:122–124.
36.
WenzelJ, van HoltN, MaierJ, et al.JAK1/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus. J Invest Dermatol, 2016; 136:1281–1283.
37.
BloomfieldM, KanderováV, ParačkováZ, et al.Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-function mutation. J Clin Immunol, 2018; 38:589–601.
38.
WeiJJ, KallenbachLR, KreiderM, et al.Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera. JAAD Case Rep, 2019; 5:360–361.
39.
LadislauL, Suárez-CalvetX, ToquetS, et al.JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain, 2018; 141(6):1609–1621.
40.
AeschlimannFA, FrémondML, DuffyD, et al.A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain, 2018; 141:e80.
41.
HornungT, JanzenV, HeidgenFJ, et al.Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med, 2014; 371:2537–2538.
42.
KingB, LeeAI, ChoiJ. Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib. J Invest Dermatol, 2017; 13:951–954.
43.
SongJ, SongA, PalmaresT, et al.Ruxolitinib found to cause eyelash growth: a case report. J Med Case Rep, 2017; 11:189.
44.
ChenCY, ChiuCF, BaiLY. Treatment of pembrolizumab-induced cutaneous lesions with ruxolitinib. Eur J Cancer, 2019; 113:69–71.
45.
LeeJJ, EnglishJC 3rd. Improvement in ulcerative necrobiosis lipoidica after Janus kinase–inhibitor therapy for polycythemia vera. JAMA Dermatol, 2018; 154(6):733–734.
46.
NasifogluS, HeinrichB, WelzelJ. Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor. Br J Dermatol, 2018; 179:504–505.
47.
FremondML, RoderoMP, JeremiahN, et al.Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol, 2016; 138:1752–1755.
48.
VolpiS, InsalacoA, CaorsiR, et al.Efficacy and adverse events during Janus kinase inhibitor treatment of SAVI syndrome. J Clin Immunol, 2019; 39:476–485.
49.
SaldanhaRG, BalkaKR, DavidsonS, et al.A mutation outside the dimerization domain causing atypical STING-associated vasculopathy with onset in infancy. Front Immunol, 2018; 9:1535.
50.
BalciS, EkinciRMK, de JesusAA, et al.Baricitinib experience on STING-associated vasculopathy with onset in infancy: a representative case from Turkey. Clin Immunol, 2020; 212:108273.
51.
FukunagaA, ItoM, NihigoriC. Efficacy of oral ruxolitinib in a patient with refractory chronic spontaneous urticaria. Acta Derm Venereol, 2018; 98:904–905.
52.
YacoubA, ProchaskaL. Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis. Biomark Res, 2016; 4:2.
53.
AlsohimeF, Martin-FernandezM, TemsahMH, et al.JAK inhibitor therapy in a child with inherited USP18 deficiency. N Engl J Med, 2020; 382:256–265.
54.
ClinicalTrials.gov. A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis. Bethesda, MD: National Library of Medicine; 2019.
55.
ClinicalTrials.gov. A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis. Bethesda, MD: National Library of Medicine; 2017.
56.
ClinicalTrials.gov. TRuE AD2—An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis. Bethesda, MD: National Library of Medicine; 2018.
57.
ClinicalTrials.gov. TRuE AD1—An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis. Bethesda, MD: National Library of Medicine; 2018.
58.
ClinicalTrials.gov. Topical Ruxolitinib Lichen Planus. Bethesda, MD: National Library of Medicine; 2018.
59.
ClinicalTrials.gov. A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis. Bethesda, MD: National Library of Medicine; 2009.
60.
ClinicalTrials.gov. Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis. Bethesda, MD: National Library of Medicine; 2008.
61.
ClinicalTrials.gov. A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis. Bethesda, MD: National Library of Medicine; 2008.
62.
ClinicalTrials.gov. Topical Ruxolitinib for the Treatment of Vitiligo. Bethesda, MD: National Library of Medicine; 2016.
63.
ClinicalTrials.gov. A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo. Bethesda, MD: National Library of Medicine; 2017.
64.
ClinicalTrials.gov. Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2). Bethesda, MD: National Library of Medicine; 2019.
65.
ClinicalTrials.gov. Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1). Bethesda, MD: National Library of Medicine; 2019.
